Bull case
The bull case prices VTR at 23x on FY1 earnings, assuming continued execution and no meaningful deceleration in the core business.
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Three scenarios for where VTR stock could go
The bull case prices VTR at 23x on FY1 earnings, assuming continued execution and no meaningful deceleration in the core business.
At 74x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
If investor confidence fades or macro conditions deteriorate, a 111x multiple contraction could push VTR down roughly 94% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.

Ventas is a healthcare-focused real estate investment trust that owns and operates senior housing communities, medical office buildings, and life science research facilities. It generates revenue primarily through rental income from its diversified portfolio — roughly 60% from senior housing, 25% from medical office buildings, and 15% from life science and hospital properties. The company's competitive advantage lies in its scale, diversified healthcare property portfolio, and long-term relationships with leading healthcare operators across multiple care settings.
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $0.87/$0.85 | +2.4% | $1.4B/$1.4B | +1.1% |
| Q4 2025 | $0.88/$0.87 | +1.1% | $1.5B/$1.5B | -2.8% |
| Q1 2026 | $0.15/$0.10 | +49.0% | $1.6B/$1.5B | +4.1% |
| Q2 2026 | $0.11/$0.12 | -10.5% | $1.7B/$1.6B | +4.5% |
VTR beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest annual revenue by segment or product family
Tap, hover, or focus a slice to inspect segment detail.
Latest annual revenue by reported region
Tap, hover, or focus a slice to inspect segment detail.
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Fair value est. $59 — implies -33.0% from today's price.
| Metric | VTR | S&P 500 | Real Estate | 5Y Avg VTR |
|---|---|---|---|---|
| Forward PE | 118.3x | 19.1x+520% | 26.4x+349% | — |
| Trailing PE | 160.7x | 25.1x+540% | 24.1x+566% | 143.3x+12% |
| PEG Ratio | — | 1.72x | 1.25x | — |
| EV/EBITDA | 24.4x | 15.2x+60% | 16.7x+46% | 19.2x+27% |
| Price/FCF | 31.3x | 21.1x+49% | 15.4x+103% | 22.6x+38% |
| Price/Sales | 7.1x | 3.1x+126% | 3.0x+138% | 5.0x+42% |
| Dividend Yield | 2.14% | 1.87% | 4.66% | 3.35% |
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolVTR pays 2.1% total shareholder yield with 13.4% operating margin. Leverage is structural for REITs — debt capacity matters more than absolute ratio.
Revenue, margins, and distribution coverage
ROIC, leverage, and debt serviceability
Asset-heavy model means debt/FCF above 10× is common and not a distress signal.
How capital is returned to owners
All figures from the trailing twelve months. REITs carry structural leverage — debt/FCF ratios above 10× are normal and do not indicate distress.
Open full ratios pageKey factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 11, 2026
Ventas carries a substantial debt load, with leverage exceeding many peers. This exposes the REIT to interest rate risk, as rising rates could increase borrowing costs and compress cash flow. The company is actively using equity to improve its credit profile, but the current debt level remains a significant risk.
Ventas trades at high valuation multiples, with a P/B ratio above the S&P 500 average and an EV/EBITDA considered "rich". This implies the market expects near‑perfect growth, creating a risk if performance fails to meet lofty expectations. A downturn could lead to a sharp decline in share price.
Ventas relies on third‑party operators for its Senior Housing Operating Portfolio. If operators underperform or labor cost pressures persist, margin expansion could slow, impacting profitability. The dependence on external operators adds execution risk.
Property‑level operating expenses for senior housing have increased, indicating a need for Ventas to optimize operational efficiency. Higher costs could erode operating margins if not controlled. The company must manage expense growth to maintain profitability.
The healthcare real estate market is highly competitive, with many players vying for properties and tenants. Intense competition can limit Ventas's ability to raise rents and drive profitability. Market share erosion could pressure earnings.
Ventas's performance is closely tied to the healthcare and senior living sectors, which are subject to regulatory changes and economic fluctuations. Policy shifts or downturns could reduce occupancy rates and rental income. This sector concentration adds risk to the company's revenue stream.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 11, 2026
Multiple analysts have issued "Buy" ratings for VTR, with a consensus rating of "Moderate Buy" and several recent upgrades and price target increases. The strong analyst sentiment signals confidence in the company’s trajectory.
Ventas has demonstrated year‑over‑year revenue growth of approximately 21.7%, outpacing U.S. market benchmarks. This robust top‑line expansion supports continued scale and market share gains.
The company has shown improving profit margins and a return to profitability, with Funds From Operations (FFO) rising significantly. Consistent EPS beats in recent quarters further underscore operational strength.
Ventas’ portfolio includes a significant number of senior housing communities, positioning it to benefit from an aging population. Demand for senior housing is expected to surge while supply growth remains low, creating a favorable supply‑demand dynamic.
Ventas recently increased its dividend, signaling confidence in cash flow and rewarding shareholders. The company is actively investing in senior housing, targeting profitable organic and external growth.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
VTR VTR Ventas, Inc. | $41.3B | 118.3x | +13.6% | 4.2% | Buy | +4.6% |
WEL WELL Welltower Inc. | $150.1B | 78.9x | +23.6% | 12.3% | Buy | +5.7% |
HR HR Healthcare Realty Trust Incorporated | $6.9B | — | +0.7% | -17.5% | Hold | -3.0% |
OHI OHI Omega Healthcare Investors, Inc. | $13.7B | 23.4x | +7.8% | 51.0% | Hold | +6.5% |
SBR SBRA Sabra Health Care REIT, Inc. | $5.1B | 29.5x | +8.3% | 19.2% | Hold | +4.0% |
NHI NHI National Health Investors, Inc. | $3.5B | 21.6x | +4.0% | 36.8% | Hold | +16.8% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
VTR returns 2.1% total yield, led by a 2.14% dividend.
Yield, cadence, and growth quality
How much per-share support comes from repurchases
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.52 | — | — | — |
| 2025 | $1.92 | +6.7% | 0.0% | 2.4% |
| 2024 | $1.80 | 0.0% | 0.0% | 3.0% |
| 2023 | $1.80 | 0.0% | 0.0% | 3.6% |
| 2022 | $1.80 | 0.0% | 0.0% | 4.3% |
Common questions answered from live analyst data and company financials.
Ventas, Inc. (VTR) is rated Buy by Wall Street analysts as of 2026. Of 32 analysts covering the stock, 19 rate it Buy or Strong Buy, 11 rate it Hold, and 2 rate it Sell or Strong Sell. The consensus 12-month price target is $91, implying +4.6% from the current price of $87. The bear case scenario is $5 and the bull case is $17.
The Wall Street consensus price target for VTR is $91 based on 32 analyst estimates. The high-end target is $100 (+15.2% from today), and the low-end target is $85 (-2.1%). The base case model target is $54.
VTR trades at 118.3x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals significantly overvalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
The primary risks for VTR in 2026 are: (1) Debt Burden — Ventas carries a substantial debt load, with leverage exceeding many peers. (2) Rich Valuation — Ventas trades at high valuation multiples, with a P/B ratio above the S&P 500 average and an EV/EBITDA considered "rich". (3) Operator Performance — Ventas relies on third‑party operators for its Senior Housing Operating Portfolio. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
Analyst consensus estimates VTR will report consensus revenue of $7.0B (+13.6% year-over-year) and EPS of $0.60 (+12.5% year-over-year) for the upcoming fiscal year. The following year, analysts project $7.9B in revenue.
A confirmed upcoming earnings date for VTR is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
Ventas, Inc. (VTR) generated $1.4B in free cash flow over the trailing twelve months — a free cash flow margin of 22.4%. VTR returns capital to shareholders through dividends (2.1% yield) and share repurchases ($0 TTM).